ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

ENABLEX
Overactive bladder/enuresis
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

ENABLEX Rx

Generic Name and Formulations:
Darifenacin (as HBr) 7.5mg, 15mg; ext-rel tabs.

Company:
Allergan

Therapeutic Use:

Indications for ENABLEX:

Overactive bladder with symptoms of urge urinary incontinence, urgency and frequency.

Adult:

Swallow whole with liquid. Initially 7.5mg once daily; may increase to 15mg once daily after 2 weeks. Moderate hepatic impairment (Child-Pugh B), concomitant potent CYP3A4 inhibitors: max 7.5mg once daily.

Children:

Not established.

Contraindications:

Patients with or at risk for: urinary or gastric retention, uncontrolled narrow-angle glaucoma.

Warnings/Precautions:

Severe hepatic impairment: not recommended. Bladder outflow obstruction. GI obstruction. Severe constipation. Ulcerative colitis. Myasthenia gravis. Controlled narrow-angle glaucoma. Monitor for CNS effects esp. after initiation or dose increases; consider reducing dose or discontinue if occurs. High environmental temperatures. Pregnancy (Cat.C). Nursing mothers.

Pharmacological Class:

Muscarinic antagonist.

Interactions:

Potentiated by potent CYP3A4 inhibitors (eg, ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin, nefazadone); see Adult. May potentiate CYP2D6 substrates with narrow therapeutic indexes (eg, flecainide, thioridazine, TCAs). Additive anticholinergic effects with other anticholinergics.

Adverse Reactions:

Constipation, dry mouth, headache, dyspepsia, nausea, UTI, accidental injury, flu symptoms; angioedema (discontinue if occurs), CNS effects (eg, confusion, hallucination, somnolence).

How Supplied:

Tabs—30, 90


Data provided by MPR.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs